Blood coagulation factor Ⅺ:new strategy of targeted anticoagulant therapy
10.11665/j.issn.1000-5048.2023050101
- VernacularTitle:凝血因子Ⅺ——靶向抗凝治疗新策略
- Author:
Kai HOU
1
;
Ping LI
;
Jinlian ZHANG
;
Fang WANG
;
Yu YANG
Author Information
1. 东南大学附属中大医院药学部,南京 210009
- Keywords:
anticoagulant therapy;
thrombosis;
coagulation;
factor Ⅺ;
novel target
- From:
Journal of China Pharmaceutical University
2024;55(5):708-714
- CountryChina
- Language:Chinese
-
Abstract:
Thrombotic disease remains a leading cause of morbidity and mortality worldwide.Despite breakthroughs in anticoagulant therapy over the past decade,traditional vitamin K antagonists have been replaced by direct oral anticoagulants(DOACs)that selectively target coagulation factor Ⅹa or Ⅱa.However,for the growing population with concomitant diseases,there is still a lack of satisfactory treatment options.Coagulation-targeted therapy is a challenging task because it interferes with the delicate balance between procoagulant and anticoagulant activities.Epidemiological and animal studies have identified factor Ⅺ as a potential target for anticoagulation,because factor Ⅺ deficiency or inhibition can prevent thrombosis and is associated with little or no bleeding.Based on the concept of contact hemostasis,this review describes the basic principles of the development of coagulation factor Ⅺ inhibitors,elaborates on the pharmacological characteristics of existing factor Ⅺ inhibitors,and summarizes the current situation of clinical trial research,to provide some insight for the development of new anticoagulant drugs and clinical anticoagulant treatment.
